Evidence Grade A — Regulatory approved. 2953 published studies. 172 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Teriparatide (sold as Forteo and generics) is a bone-building medication used for severe osteoporosis — it was the first treatment that actually stimulates the formation of new bone, rather than just slowing bone loss. Given as a daily injection, it reduced spinal fractures by 65% in its landmark trial. It is now available as a generic, making it more accessible than ever.
Teriparatide is also known by these brand and alternate names:
2,953 published studies: 2073 human, 175 animal, 82 in-vitro, 854 reviews
Teriparatide is marketed as Forteo (approved November 2002), with generic versions available since 2023. It is indicated for osteoporosis in postmenopausal women and men at high fracture risk. The landmark Fracture Prevention Trial demonstrated a 65% reduction in vertebral fractures and a 53% reduction in non-vertebral fractures compared to placebo.
Treatment is limited to two years due to a preclinical finding of bone tumours in rats given high doses over their lifetime — though this has never been observed in humans over two decades of clinical use. After stopping teriparatide, patients typically transition to an anti-resorptive medication (like a bisphosphonate) to maintain the bone gains. Teriparatide is now facing competition from abaloparatide, which works through a related but distinct mechanism, and romosozumab, a non-peptide monoclonal antibody with dual anabolic and anti-resorptive action.
This is where teriparatide gets counterintuitive: parathyroid hormone continuously elevated in the blood actually breaks bone down (as seen in hyperparathyroidism). But when given as a brief daily pulse — a single injection that spikes then clears — it has the opposite effect: it stimulates bone-building cells (osteoblasts) to form new bone. This intermittent exposure activates growth and survival signals in osteoblasts without triggering the bone-resorption pathway. The result is genuine new bone formation, not just preservation of existing bone.
The Fracture Prevention Trial demonstrated a 65% reduction in vertebral fractures and 53% reduction in non-vertebral fractures compared to placebo — establishing teriparatide as a cornerstone treatment for severe osteoporosis. Over 20 years of use have confirmed its safety and effectiveness. Generic availability since 2023 has significantly improved access. Treatment was historically limited to two years due to a preclinical finding of bone tumours in rats, though this has never been observed in humans despite two decades of monitoring. The standard approach is to follow teriparatide with an anti-resorptive medication (like a bisphosphonate) to maintain the bone gains — the sequential therapy paradigm is now well established. Teriparatide faces competition from abaloparatide (a related bone-builder) and romosozumab (a non-peptide monoclonal antibody with both bone-building and bone-preserving effects).
PeptideTrace tracks 172 registered clinical trials for Teriparatide sourced from ClinicalTrials.gov.
A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
FDA ORIG 1
FDA SUPPL 2
Health Canada Market Authorisation
FDA SUPPL 4
FDA SUPPL 9
FDA SUPPL 15
FDA SUPPL 16
FDA SUPPL 12
FDA SUPPL 26
FDA SUPPL 27
FDA SUPPL 32
FDA SUPPL 33
FDA SUPPL 35
FDA SUPPL 36
FDA SUPPL 38
FDA SUPPL 37
FDA SUPPL 39
FDA SUPPL 40
FDA SUPPL 41
FDA SUPPL 44
FDA SUPPL 51
FDA SUPPL 52
FDA ORIG 1
FDA SUPPL 53
FDA SUPPL 54
FDA SUPPL 56
FDA ORIG 1
FDA SUPPL 4
FDA ORIG 1
FDA SUPPL 57
FDA SUPPL 6
FDA SUPPL 1
FDA SUPPL 17
FDA ORIG 1
Teriparatide is the recombinant 34-amino-acid N-terminal fragment of human parathyroid hormone, PTH(1-34). This fragment retains full biological activity at the PTH1 receptor. It was the first anabolic agent approved for osteoporosis.
Teriparatide activates the PTH1 receptor (PTH1R) on osteoblasts. The anabolic effect depends on intermittent exposure: brief, daily receptor activation produces transient cAMP signaling that upregulates genes promoting osteoblast differentiation, survival, and bone formation (Wnt signaling, RUNX2). This contrasts with continuous PTH exposure (as in hyperparathyroidism), which upregulates RANKL on osteoblasts, stimulating osteoclastogenesis and net bone resorption.
Teriparatide is marketed as Forteo (approved November 26, 2002). Generic teriparatide became available in 2023 (Teva, Ambio). Indicated for osteoporosis in postmenopausal women and men at high fracture risk. The Fracture Prevention Trial (N=1,637; NEJM 2001) demonstrated a 65% reduction in vertebral fractures (RR 0.35), 53% reduction in nonvertebral fractures (RR 0.47), and lumbar spine BMD increase of 9%. The original 24-month treatment limit (based on osteosarcoma in Fischer 344 rats at near-lifetime exposure) has been relaxed—the post-marketing registry showed no increased human osteosarcoma risk, and the boxed warning has been removed.
Compare prices from 1 vendor listing
View pricing data across vendors and countries for Teriparatide
Linaclotide is marketed as Linzess (approved August 2012). It is taken as a daily oral capsule on an empty stomach, at least 30 minutes before the first meal. The recommended dose is 290 mcg for IBS-C and 72 or 145 mcg for chronic constipation. In clinical trials, approximately 34% of IBS-C patients met the composite improvement endpoint compared to 17% on placebo. Diarrhoea is the most common side effect (approximately 20%) and the leading reason for discontinuation. Linaclotide has a boxed warning against use in children under 6 years due to deaths in young mice, though no such events have been reported in humans. It competes with plecanatide (which targets the same pathway) and other IBS-C treatments.
Elamipretide (Forzinity) was approved by the FDA for Barth syndrome based on the TAZPOWER trial. The randomised crossover phase (12 patients) did not meet its primary endpoints, but the open-label extension (168 weeks) demonstrated durable improvements in walking distance and muscle strength that formed the basis for approval. Barth syndrome affects approximately 1 in 300,000–400,000 births. A larger Phase III trial in primary mitochondrial myopathy (218 patients, MMPOWER-3) did not meet its primary endpoint, and the drug was not approved for that broader indication. Elamipretide remains approved exclusively for Barth syndrome. See also SS-31 (#158) for the research compound context.
Glucagon has been available as an emergency injection since the 1960s and remains the standard rescue treatment for severe hypoglycaemia. Recent innovation has focused on making it easier to administer in emergencies. Baqsimi, approved in 2019, was the first needle-free option as a nasal powder. Gvoke, also approved in 2019, eliminated the need to mix and reconstitute the medication before injection — a significant advance since severe hypoglycaemia often impairs the ability to follow complex preparation steps. Dasiglucagon (Zegalogue), a next-generation stable liquid glucagon approved in 2021, further improved on the convenience of rescue administration. Beyond emergency rescue, glucagon's receptor is now a major research target — dual and triple agonists combining glucagon receptor activity with GLP-1 (such as survodutide and retatrutide) are in advanced clinical trials for obesity and metabolic disease.
Comparisons
Evidence Reviews
Timelines
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
